**Core Concept:** Rocuronium is a non-depolarizing neuromuscular blocking agent that inhibits the acetylcholine-binding to the nicotinic receptors at the neuromuscular junction, leading to muscle relaxation. To reverse its effect, a specific antagonist is needed.

**Why the Correct Answer is Right:** The correct answer, **Dantrolene**, is a specific antagonist for ryanodine receptors, which are calcium channels involved in the release of calcium ions from sarcoplasmic reticulum in muscle cells. Dantrolene competitively inhibits the release of calcium ions, thus counteracting the effect of rocuronium, a calcium channel agonist, and restoring neuromuscular function.

**Why Each Wrong Option is Incorrect:**

A. **Dexamethasone:** A corticosteroid used for its anti-inflammatory and immunosuppressive actions, dexamethasone is not a specific antagonist for ryanodine receptors and does not reverse rocuronium's effect effectively.

B. **Atropine:** A competitive antagonist for muscarinic cholinergic receptors, atropine reverses the effect of drugs like atropine, but it does not target the ryanodine receptors involved in rocuronium's action.

C. **Neostigmine:** A competitive antagonist for muscarinic cholinergic receptors, neostigmine is used for reversing the effect of other non-depolarizing neuromuscular blocking agents like vecuronium and pancuronium, but it is not effective against rocuronium due to its action on different receptors.

**Clinical Pearl:** In clinical practice, dantrolene is a preferred choice for reversing the effect of rocuronium, particularly for short-term reversal or in situations where a rapid onset of muscle relaxation is required. However, there are other options available for prolonged reversal such as sugammadex and neostigmine.

**Correct Answer Explanation:** Dantrolene is the correct answer because it competitively inhibits the release of calcium ions from sarcoplasmic reticulum, effectively counteracting the effect of rocuronium, a calcium channel agonist.